Anemia and fibroblast growth factor 23 elevation in chronic kidney disease: homeostatic interactions and emerging therapeutics
- 10 June 2022
- journal article
- review article
- Published by Wolters Kluwer Health in Current Opinion in Nephrology and Hypertension
- Vol. 31 (4) , 320-325
Abstract
Purpose of review: Chronic kidney disease (CKD) is a progressive disorder that is associated with development of elevated fibroblast growth factor 23 (FGF23) levels and anemia. Here, we review recent literature that extends our current knowledge on the interactions between FGF23 and anemia in CKD and the impact of anemia-targeting therapeutics on FGF23 elevation in CKD. Recent findings: The anemia of CKD is primarily driven by a lack of erythropoietin (EPO) and iron deficiency. In addition to EPO and iron replacement, novel drug classes to treat anemia have been approved or are in clinical development. A recent observational study provides supportive evidence for the hypothesis that FGF23 elevation in CKD mediates adverse effects of iron deficiency on the cardiovascular system in patients with CKD. Preclinical and clinical studies revealed that ferric citrate (FC), and hypoxia-induced factor-prolyl hydroxylase inhibitor (HIF-PHI) treatment may reduce elevated FGF23 levels in CKD, suggesting that correcting anemia in CKD could potentially lower FGF23 levels. However, as we describe, HIF-PHI have context-dependent effects. Moreover, whether a reduction in FGF23 will improve patient outcomes in patients with CKD remains to be determined. Summary: With the emergence of novel therapeutics to treat oxygen and iron utilization deficits in CKD, studies have investigated the impact of these new drugs on FGF23. Several of these drugs, including FC and HIF-PHIs, alleviate iron homeostasis alterations in CKD and are associated with FGF23 reduction. Herein, we review the relationships between oxygen/iron sensing and FGF23 in CKD, recent findings which link FGF23 with cardiac dysfunction, as well as future translational and clinical avenues.Keywords
This publication has 52 references indexed in Scilit:
- FGF23 neutralization improves chronic kidney disease–associated hyperparathyroidism yet increases mortalityJournal of Clinical Investigation, 2012
- Regulation and Function of the FGF23/Klotho Endocrine PathwaysPhysiological Reviews, 2012
- FGF23 induces left ventricular hypertrophyJournal of Clinical Investigation, 2011
- Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in miceProceedings of the National Academy of Sciences, 2011
- FGF-23 Associates with Death, Cardiovascular Events, and Initiation of Chronic DialysisJournal of the American Society of Nephrology, 2011
- Fibroblast Growth Factor 23 and Risks of Mortality and End-Stage Renal Disease in Patients With Chronic Kidney DiseaseJAMA, 2011
- Klotho Deficiency Causes Vascular Calcification in Chronic Kidney DiseaseJournal of the American Society of Nephrology, 2011
- Altered renal FGF23-mediated activity involving MAPK and Wnt: effects of the Hyp mutationJournal of Endocrinology, 2010
- Circulating Fibroblast Growth Factor 23 in Patients with End-Stage Renal Disease Treated by Peritoneal Dialysis Is Intact and Biologically ActiveThe Journal of Clinical Endocrinology & Metabolism, 2010
- Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formationProceedings of the National Academy of Sciences, 2009